Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

Boehringer Ingelheim
Cipla
Accenture
Medtronic
QuintilesIMS
Queensland Health
Merck
Mallinckrodt
UBS

Generated: November 18, 2018

DrugPatentWatch Database Preview

Drugs in Development Information for Belimumab

« Back to Dashboard

US Patents for Belimumab

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Belimumab ➤ Sign Up Compositions and methods for treating or preventing lupus The United States of America, as represented by the Secretary, Department of Health & Human Services (Washington, DC) ➤ Sign Up
Belimumab ➤ Sign Up Pretreatment of a biological sample from an autoimmune disease subject Genentech, Inc. (South San Francisco, CA) ➤ Sign Up
Belimumab ➤ Sign Up Stabilizing alkylglycoside compositions and methods thereof Aegis Therapeutics LLC (San Diego, CA) ➤ Sign Up
Belimumab ➤ Sign Up P97 fragments with transfer activity biOasis Technologies, Inc. (Vancouver, British Columbia, unknown) ➤ Sign Up
Belimumab ➤ Sign Up Methods and compositions for treating lupus Natrogen Therapeutics International, Inc. (New York, NY) ➤ Sign Up
Drugname Patent Number Patent Title Patent Assignee Estimated Expiration

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

International Patents for Belimumab

Drugname Country Document Number Estimated Expiration Related US Patent
Belimumab Australia 2010364324 2030-11-24 ➤ Sign Up
Belimumab Canada 2818712 2030-11-24 ➤ Sign Up
Belimumab Japan 2014505020 2030-11-24 ➤ Sign Up
Belimumab Japan 5850943 2030-11-24 ➤ Sign Up
Belimumab South Korea 101813482 2030-11-24 ➤ Sign Up
Drugname Country Document Number Estimated Expiration Related US Patent

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Fuji
Moodys
QuintilesIMS
Chubb
Colorcon
Cipla
Argus Health
Federal Trade Commission
Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.